Sweden· SE-20220304000085
Tevimbra 100 mg Koncentrat till infusionsvätska, lösning
A medicinal product containing tislelizumab, registered in Sweden by BeOne Medicines Ireland Limited.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Tislelizumab
- Manufacturer
- BeOne Medicines Ireland Limited
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20220304000085
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tislelizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTevimbra 100 mgBeOne Medicines Ireland
- CzechiaTEVIMBRABeOne Medicines Ireland Limited, Dublin
- FinlandTevimbraBeOne Medicines Ireland Limited
- IrelandTevimbra 100 mg concentrate for solution for infusionBeiGene Ireland Limited
- IcelandTevimbraBeigene Ireland Limited
- NorwayTevimbraBeOne Medicines Ireland Limited
- PolandTizveniBeiGene Ireland Ltd.
- United StatesTEVIMBRABeOne Medicines USA, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tevimbra
- Norway · Tevimbra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d38e29b8-e1f5-472c-be54-f11d31c9086e GET /v1/drugs/d38e29b8-e1f5-472c-be54-f11d31c9086e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20220304000085",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20220304000085",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra"
}See everything about tislelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.